Products
-
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
K 114 (AC216)
Cat.#: ASSD-216
Specifications
Description K 114, a potent amyloid fibril-specific fluorescent dye, is similar to Congo Red. The product is used to recognize amyloid lesions and quantitative monitoring of the formation of amyloid fibrils assembled from the Aβ peptide, α-synuclein, and tau. Synonyms (trans,trans)-1-Bromo-2,5-bis-(4-hydroxy)styrylbenzene; K114 Size 10 mg, 50 mg Applications Potent amyloid fibril-specific fluorescent dye Molecule Weight 393.27 Molecular formula C22H17BrO2 CAS Number 872201-12-2 MDL Number MFCD11045294 Purity ≥98% Solubility Soluble in DMSO (100 mM ), and ethanol (50 mM ). Storage Store at 4° C Shipping Shipped at 4°C Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Size Price ASSD-131 Calcein Blue (AC131) 1 mg inquiry ASSD-179 8-Azidoadenosine-5′-diphosphate Sodium Salt (AC179) 1 mg, 5 mg inquiry ASSD-180 Ru(bpy)2(mcbpy-O-Su-ester)(PF6)2 (AC180) 1 mg inquiry ASSD-103 DAPI Staining Solution (1mg/mL) (AC103) 1 mL, 5 mL, inquiry ASSD-170 BAPTA-AM (AC170) 25 mg inquiry ASSD-200 Ethylenediamine N-[(Cyanine 3) Monofunctional Hexanoic Acid]-N′-[3-difluoromethyl-4-phosphoanilinamidosuccinic Acid] Diamide (AC200) 500 μg inquiry ASSD-145 Oxazole Yellow Iodide 1mM solution (in 1mL DMSO) (AC145) 1 mL inquiry ASSD-198 NHS-5(6)Carboxyrhodamine (AC198) 25 mg inquiry ASSD-115 7-Amino-4-methylcoumarin (AC115) 100 mg, 500 mg, 1 g inquiry ASSD-185 Cyanine 3 Maleimide, Potassium Salt (AC185) 500 μg inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
Quick Links0Inquiry Basket